Latest available resultsQuarter ended June 30, 202610-Q · August 4, 2026
Filed with the SECEdwards Lifesciences Corp
EWHealthcare
Next reportOctober 28, 2026after close · Analyst forecast 0.758 $/share
Revenue
$1.74B
▲ +13.6% vs prior year% YoY
Net income
$241.90M
▼ -27.4% vs prior year% YoY
EPS
0.42$
▼ -25.0% vs prior year% YoY
Net margin
13.9%
▼ -7.9 percentage points vs prior year pp YoY
Revenue▲ +13.6 %
Margins (% of revenue)GrossOperatingNet
Net income▼ -27.4 %
EPS▼ -25.0 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $1.74B | |
| Gross profit | $1.35B | 77.5 % |
| Operating income | $513.20M | 29.5 % |
| Net income | $241.90M | 13.9 % |
| R&D | $278.90M | 16.0 % |
| EPS (diluted) | 0.42 $ | |
| Balance sheet | ||
| Assets | $13.87B | |
| Liabilities | $3.14B | |
| Equity | $10.72B | |
| Cash | $2.91B | |
| Capital | ||
| Shares outstanding | 576.40M | as of 2026-07-31 |
| Public float | — | |